Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience.
Sign Up to like & getrecommendations! Published in 2020 at "Contemporary clinical trials"
DOI: 10.1016/j.cct.2020.106179
Abstract: The phase III, randomized, active-controlled, multicenter, open-label KEYNOTE-183 study (NCT02576977) evaluating pomalidomide and low dose dexamethasone (standard-of-care [SOC]) with or without pembrolizumab in patients with refractory or relapsed and refractory multiple myeloma (rrMM) was placed… read more here.
Keywords: using artificial; multiple myeloma; ecog performance; keynote 183 ... See more keywords